The National Pharmaceutical Pricing Authority (NPPA) has reduced the MRP of 390 non-scheduled cancer medicines have been reduced by up to 87%. NPA has asked the manufacturers and hospitals to revise the prices based on the trade margin formula.
The release by the NPPA states that five brands will see a price reduction of about 70%, while 12 others will see a 50-70% price cut. MRPs of 45 cancer medicines will reduce by 25%…
National Pharmaceutical Pricing Authority (NPPA) constituted in 1997 is an independent Regulator for pricing of drugs and to ensure availability and accessibility of medicines at affordable prices under the Ministry of Chemicals & Fertilizers. NPPA Implement and enforce the provisions of the Drugs (Prices Control) Order, monitor the availability of drugs, identify shortages, if any, and to take remedial steps, maintain data on production, exports, and imports, the market share of individual companies, the profitability of companies etc, for bulk and formulations.
NPPA implements the National Pharmaceutical Pricing Policy 2012. NPPA provides ceiling price to all Drugs notified under Schedule-I of the DPCO, 2013.